Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EBITDA: 2011-2025

Historic EBITDA for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to -$1.5 million.

  • Sunshine Biopharma's EBITDA fell 329.12% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 52.09%. This contributed to the annual value of -$6.7 million for FY2024, which is 67.69% down from last year.
  • Sunshine Biopharma's EBITDA amounted to -$1.5 million in Q3 2025, which was down 116.45% from -$686,277 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's EBITDA registered a high of $701,988 during Q4 2021, and its lowest value of -$23.3 million during Q4 2022.
  • Over the past 3 years, Sunshine Biopharma's median EBITDA value was -$1.2 million (recorded in 2025), while the average stood at -$1.3 million.
  • Data for Sunshine Biopharma's EBITDA shows a peak YoY increase of 164.85% (in 2021) and a maximum YoY decrease of 6,371.96% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's EBITDA stood at $701,988 in 2021, then plummeted by 3,414.95% to -$23.3 million in 2022, then skyrocketed by 96.74% to -$758,468 in 2023, then tumbled by 316.20% to -$3.2 million in 2024, then tumbled by 329.12% to -$1.5 million in 2025.
  • Its EBITDA was -$1.5 million in Q3 2025, compared to -$686,277 in Q2 2025 and -$1.2 million in Q1 2025.